Retrospective analysis of efficacy and safety of Gemcitabinebased chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX

Advanced pancreatic adenocarcinoma still carries a dismal prognosis; less than 1% of patients are alive 5 years after the discovery of metastasis (1). Despite recent advances in cytotoxic chemotherapy in the first-line setting (2,3), virtually all patients experience disease progression when treated with FOLFIRINOX or Gemcitabine plus Nab-Paclitaxel. Hence, patients frequently need additional treatments to palliate symptoms and extend survival